Protagonist Therapeutics Inc (PTGX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 44.31% | -18.85% | 0.92% | -71.66% | -13,442.37% |
| Operating profit margin | -155.73% | -491.96% | -458.49% | -234.31% | -68,238.14% |
| Pretax margin | -131.29% | -477.06% | -457.41% | -235.53% | -65,998.31% |
| Net profit margin | -131.29% | -477.06% | -457.41% | -240.25% | -65,412.71% |
Protagonist Therapeutics Inc has displayed varying levels of profitability over the last five years. The gross profit margin has shown improvement, increasing from negative figures in 2019 and 2020 to positive percentages in 2021, 2022, and 2023. This indicates that the company is effectively managing its production costs and generating a higher proportion of revenue as gross profit.
However, the operating profit margin, pretax margin, and net profit margin have remained consistently negative over the five-year period, with 2023 showing slightly less negative margins compared to previous years. The significant negative margins suggest that the company's operating expenses, taxes, and net profits have not been favorable in relation to revenue.
Overall, Protagonist Therapeutics Inc needs to focus on improving operational efficiency, controlling costs, and increasing revenue generation to achieve sustainable profitability in the future.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -26.16% | -52.99% | -36.19% | -19.88% | -51.98% |
| Return on assets (ROA) | -22.06% | -51.38% | -36.11% | -20.39% | -49.82% |
| Return on total capital | -27.82% | -60.93% | -41.95% | -22.98% | -97.18% |
| Return on equity (ROE) | -23.45% | -59.09% | -41.85% | -23.66% | -96.53% |
Protagonist Therapeutics Inc's profitability ratios show a concerning trend over the past five years. The company's operating return on assets (Operating ROA) has been consistently negative, indicating that its core operations have not been generating satisfactory returns on its assets. Similarly, the return on assets (ROA) and return on equity (ROE) have also been in negative territory, reflecting the company's inability to generate profits relative to its total assets and shareholders' equity.
Furthermore, the return on total capital, which considers both equity and debt capital, has also shown a negative trend, indicating that the company's overall capital has not been efficiently utilized to generate returns for its investors. These declining profitability ratios suggest potential inefficiencies in Protagonist Therapeutics Inc's operations and capital management, which could be a cause for concern for investors and stakeholders.
It is crucial for the company to address the underlying reasons for its poor profitability performance and implement strategies to improve its operational efficiency, utilization of capital, and overall financial performance in order to enhance shareholder value and sustainable growth in the future.